Concurrent bone-modifying agent use and fracture risk in patients treated with radium-223 for metastatic castration-resistant prostate cancer: A Japanese claims database study
OBJECTIVE: Radium-223 dichloride (Ra-223) prolongs overall survival in castration-resistant prostate cancer (CRPC) with symptomatic bone metastases, but the ERA-223 trial reported an increased fracture rate when Ra-223 was combined with an androgen receptor signaling inhibitor (ARSI), and concurrent use of a bone-modifying agent (BMA) attenuated this risk. Few studies have quantitatively characterized real-world concurrent BMA use during Ra-223 treatment in Asia, or examined its association with fracture risk with competing risks taken into account. This study aimed to describe the real-world rate of concurrent BMA use during Ra-223 treatment in Japan and to quantify its association with fracture risk. METHODS: In this retrospective observational study using the DeSC Database, a Japanese administrative claims database, 1,132 patients with a claim for Ra-223 were identified, and the date of the first claim was defined as day 0. After excluding patients with less than one year of prior observation, patients with another primary cancer, and patients who had a fracture diagnosis or the competing event of death, or whose observation ended, during the 8 weeks after day 0, the analysis set comprised 538 patients. Concurrent BMA use was defined by a claim for denosumab or zoledronic acid during the 8 weeks after day 0. The primary outcome was any fracture, identified from fracture diagnosis codes recorded after the landmark. Cumulative incidence was estimated with death as a competing event, and multivariable Fine-Gray regression and inverse probability of treatment weighting (IPTW) were applied. RESULTS: Concurrent BMA use was present in 250 patients (46.5%). Any fracture occurred in 91 patients, with a cumulative incidence of 14.1% at 12 months and 19.0% at 24 months after the landmark. Concurrent BMA use was associated with a lower fracture risk (subdistribution hazard ratio [sHR] 0.26, 95% confidence interval [CI] 0.16-0.42), whereas concurrent ARSI use (sHR 2.18, 95% CI 1.40-3.40) and a history of fracture diagnosis (sHR 2.55, 95% CI 1.32-4.92) were associated with increased risk. The IPTW analysis was concordant (sHR 0.29, 95% CI 0.18-0.47). CONCLUSIONS: Concurrent BMA use during Ra-223 treatment remained below half in Japanese real-world practice, yet was associated with a substantially lower fracture risk under competing risks.
Authors
- Keiichi Jingu (ORCID: https://orcid.org/0000-0002-7032-1577)
- Takaya Yamamoto (ORCID: https://orcid.org/0000-0003-3562-1037)
- Noriyoshi Takahashi (ORCID: https://orcid.org/0000-0002-7653-0046)
- Rei Umezawa (ORCID: https://orcid.org/0000-0002-7280-3676)
- Kazuya Takeda (ORCID: https://orcid.org/0000-0002-7354-4063)
Institutions
- Tohoku University (JP)
- Tochigi Medical Center (JP)
Publication Details
- Journal
- Annals of Nuclear Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1007/s12149-026-02318-6
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science